3.0 Disruptive Innovation

in Vaccine Manufacturing

Thomas HessHead- US Commercial June 14th, 2016

Need for 3.0 Disruptive Innovation

• Manufacturing speed always the biggest challenge to meeting EID outbreaks

• Need for 3.0 Technology Platform approach that allows for EID speed of response

• Moving from threat identification to producing a countermeasure is a long and complex process = Need for a faster platform and simplified FDA process.

Introducing the Medicago 3.0 Transient plant-based expression system:

MEDICAGO_FINAL_BILINGUAL.mp4

Introduction to

Medicago

© Medicago Inc.All rights reserved

10

CO

NFI

DEN

TIA

L

Focus Vaccines & Therapeutic Proteins

Manufacturing technology Transient expression in plants

Vaccine technology Virus-like particles

Employees ~300 Expected to grow to 500 by 2019 (commercial)

Success storyInnovative Canadian Vaccine Technology Potential advantages over current vaccine technologies (efficacy, cross protection)Pandemic Supply advantages

Headquarters, laboratories & cGMP facilities

Quebec City, CANADAResearch Triangle Park, NC, USA

Medicago Overview

Our Technology

© Medicago Inc.All rights reserved

12

CO

NFI

DEN

TIA

L

VLPExpress™:A proprietary screening platform for rapidly identifying the best VLP-based antigen target presentations for a disease-causing agentMedicago is using this platform as well to expand identification and development of therapeutic proteins (such as monoclonal antibodies) and biodefense products.

VLPs Vaccine Technology: Virus-Like-Particles (VLPs) are the most exciting emerging vaccine technology for generating effective and long-lasting protection. VLPs mimic the native structure of a virus, allowing them to be recognized readily by the immune system. However, unlike viruses, they lack the core genetic material, making them non-infectious and unable to replicate

Proficia™ technology:A proprietary alternative in manufacturing to current egg-based and cell production systems. The Proficia™ technology is a rapid, flexible, high-yielding and robust vaccine and proteins (such as antibodies) production system.

The benefits of these technologies can make a significant difference for the rapid identification, development and manufacturing of novel vaccines and therapeutic antibodies

Medicago Technologies allow for rapid identification & production of vaccines and therapeutic proteins

Emergency Preparedness

© Medicago Inc.All rights reserved

14

CO

NFI

DEN

TIA

L

To produce different strains of anti-Ebola antibodies, demonstrating the platform’s potential to respond to international emergencies and

pandemics

Medicago’s was awarded two Ebola Contacts in 2015:Collaboration with the US governmentCollaboration with the Canadian Government

© Medicago Inc.All rights reserved

15

CO

NFI

DEN

TIA

L

Avril Mai Juin Juillet Août Septembre Octobre Novembre Décembre0

20000

40000

60000

80000

100000

120000

140000

160000

180000

200000

First Responder Solution for PandemicsN

umbe

r of f

lu c

ases

wor

ldw

ide

Egg-

base

d va

ccin

es

Vacc

ines

from

Med

icag

o

Identification of strain A/H1N1

First wave begins

Second wave begins

H1N1 PandemicVaccine supply gap

April May June July August September October November December

Vaccine Discovery Program

© Medicago Inc.All rights reserved

17

CO

NFI

DEN

TIA

LVersatile Product Platform: Product pipeline

Research Preclinical Phase I Phase II Phase III

Pandemic

Seasonalquadrivalent

Rotavirus

Human Papilloma Virus

Anti-EbolamAbs

Others mAbs, including

biodefense targets

New vaccine targets

Emergency use

18-6450-64

65+

Questions